Bi-cyclic pyrimidine inhibitors of TGFβ
US7223766B2 · kind B2 · utility
25Cited by
2References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 26, 2004 |
| Grant date | May 29, 2007 |
| Priority date | — |
| Expiry date | Dec 22, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D498/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds in which a pyrimidine nucleus is bridged at the 5 and 6 position and are further substituted at positions 2 and 4 with substituents comprising aromatic moieties are useful in treating subjects with rheumatoid arthritis ameliorated by inhibition of TGFβ activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.